TAZ anticorps (Internal Region)

N° du produit ABIN7224612

L’anticorps Lapin Polyclonal anti-TAZ a été validé pour WB et ELISA. Il convient pour détecter TAZ dans des échantillons de Humain.

Aperçu rapide pour TAZ anticorps (Internal Region) (ABIN7224612)

Antigène: TAZ (Tafazzin (TAZ))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp TAZ est non-conjugé

Application: Western Blotting (WB), ELISA

Détail du produit anti-TAZ anticorps

Épitope: Internal Region

Fonction: Tafazzin Polyclonal Antibody

Specificité: Tafazzin Polyclonal Antibody detects endogenous levels of Tafazzin protein.

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen

Immunogène: Synthesized peptide derived from the Internal region of human Tafazzin

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB (1:500-1:2000), ELISA (1:5000). Not yet tested in other applications.

Commentaires:

Primary Antibody

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS containing 50 % Glycerol, 0.5 % BSA and 0.02 % Sodium Azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Détails sur TAZ

Antigène: TAZ (Tafazzin (TAZ))

Autre désignation: Tafazzin

Sujet: Rabbit Anti-Tafazzin Polyclonal Antibody,TAZ, EFE2, G4.5, Tafazzin, Protein G4.5,TAZ (tafazzin) encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in TAZ have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced, the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known.,Tafazzin

Poids moléculaire: observerd band 33kDa

ID gène: 6901

UniProt: Q16635